Trials
4 active
4 in total · 1 in the EU
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Administered intravenous (IV) in accordance with the protocol-defined requirements.”In the company’s words, NCT07623200 on ClinicalTrials.gov
- Tested for
- Myeloproliferative Neoplasms (2 trials), Essential Thrombocythemia
- Main trialPhase 3
- “This study is being conducted to evaluate INCA033989 versus best available therapy in participants with essential thrombocythemia and a CALR mutation previously treated with cytoreductive therapy.”In the company’s words, NCT07623200 on ClinicalTrials.gov
Other drugs for Myeloproliferative Neoplasms
- Givinostat HydrochlorideItalfarmaco · Phase 3
- NavitoclaxAbbVie · Phase 3
- NavtemadlinKartos Therapeutics, Inc. · Phase 3
- OlverembatinibAscentage Pharma Group Inc. · Phase 3
- Radotinib HClIl-Yang Pharm. Co., Ltd. · Phase 3
- SelinexorKaryopharm Therapeutics Inc · Phase 3
Coming up3
- 29 Feb 2028Phase 1 trial completes · ClinicalTrials.gov
- 29 Oct 2028Phase 1 trial completes · ClinicalTrials.gov
- 15 Jun 2029Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials4
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | 15 Jun 2029 | A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia | |
| Phase 1Active, not recruiting | 14 Nov 2026 | A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of INCA033989 Following Subcutaneous or Intravenous Administration in Healthy Adult Participants | |
| Phase 1Active, not recruiting | 29 Feb 2028 | A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms | |
| Phase 1Recruiting | 29 Oct 2028 | A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026